Here are four takeaways:
1. The presentations included:
- One year results of an international multi-center study of EndoStim therapy for refractory GERD
- Interim results from EndoStim’s international patient registry
- Four year outcomes of EndoStim therapy
- Effect of EndoStim on reflux mechanisms in GERD patients
2. Also presented was an additional independent study examining under-diagnosed and inadequately-treated GERD patients, titled “Inadequate Symptom Control on Long-Term PPI Therapy in GERD – Fact or Fiction?”.
3. EndoStim developed a minimally-invasive implant that restores normal esophageal function through neurostimulation.
4. The United States has not approved the EndoStim system.
More articles on GI & endoscopy:
Dr. Kenneth Chang performs 1st TIF procedure using new EsophyX Z device: 6 things to know
Double reprocessing duodenoscopes reduces infection transmission risk: 4 insights from new research
Early cancer detection found with free colonoscopies — 5 points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.